The FDA has approved Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of
primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhibiting sweat gland activation.
Approval is based on results from two Phase 3 clinical trials, ATMOS-1 and ATMOS-2, which evaluated the efficacy and safety of Qbrexza in patients with primary axillary hyperhidrosis. Both trials assessed the absolute change from baseline in sweat production (the weight or amount of sweat a patient produced) following treatment with Qbrexza and the proportion of patients who achieved at least a four-point improvement from baseline in their sweating severity, as measured by the Axillary Sweating Daily Diary (ASDD), Dermira’s proprietary patient-reported outcome (PRO) instrument. The PRO was developed in consultation with the FDA and in accordance with the agency’s 2009 guidance on PRO instruments.
Read the article Click here
Share this Article
Back to Blog Page